Renato Bernardini
Overview
Explore the profile of Renato Bernardini including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
87
Citations
1160
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Munafo A, Cantone A, Di Benedetto G, Torrisi S, Burgaletto C, Bellanca C, et al.
Front Pharmacol
. 2024 Apr;
15:1386224.
PMID: 38595916
Alzheimer's disease (AD) is the most common neurodegenerative disorder affecting the elderly population worldwide. Due to the multifactorial nature of the disease, involving impairment of cholinergic neurotransmission and immune system,...
12.
Cantone A, Burgaletto C, Di Benedetto G, Pannaccione A, Secondo A, Bellanca C, et al.
Cells
. 2024 Feb;
13(4.
PMID: 38391922
Alzheimer's disease (AD), marked by cognitive impairment, predominantly affects the brain regions regulated by cholinergic innervation, such as the cerebral cortex and hippocampus. Cholinergic dysfunction, a key contributor to age-related...
13.
Bellanca C, Augello E, Mariottini A, Bonaventura G, La Cognata V, Di Benedetto G, et al.
Curr Neuropharmacol
. 2024 Jan;
22(8):1286-1326.
PMID: 38275058
Multiple sclerosis (MS) is the most prevalent chronic autoimmune inflammatory- demyelinating disorder of the central nervous system (CNS). It usually begins in young adulthood, mainly between the second and fourth...
14.
Cantarella G, Di Benedetto G, Scollo M, Paterniti I, Cuzzocrea S, Bosco P, et al.
Neuropsychopharmacology
. 2023 Nov;
49(6):1061-1062.
PMID: 38017163
No abstract available.
15.
Bellanca C, Augello E, Cantone A, Di Mauro R, Attaguile G, Di Giovanni V, et al.
Pharmaceuticals (Basel)
. 2023 Nov;
16(11).
PMID: 38004408
The European Medicine Agency (EMA) has defined Adverse Drug Reactions (ADRs) as "a noxious and unintended response to a medicine", not including poisoning, accidental, or intentional overdoses. The ADR occurrence...
16.
Munafo A, Arillotta D, Mannaioni G, Schifano F, Bernardini R, Cantarella G
Pharmaceuticals (Basel)
. 2023 Jan;
16(1).
PMID: 36678564
Psilocybin has been suggested as a promising transdiagnostic treatment strategy for a wide range of psychiatric disorders. Recent findings showed that psychedelic-assisted/"psycholitic" psychotherapy should provide significant and sustained alleviation of...
17.
Aiello G, Cuocina M, La Via L, Messina S, Attaguile G, Cantarella G, et al.
J Clin Med
. 2023 Jan;
12(2).
PMID: 36675363
Melatonin modulates the circadian rhythm and has been studied as a preventive measure against the development of delirium in hospitalized patients. Such an effect may be more evident in patients...
18.
Marino A, Stracquadanio S, Campanella E, Munafo A, Gussio M, Ceccarelli M, et al.
Antibiotics (Basel)
. 2023 Jan;
12(1).
PMID: 36671250
Multidrug resistant Gram-negative bacteremia represents a therapeutic challenge clinicians have to deal with. This concern becomes more difficult when causing germs are represented by carbapenem resistant or difficult-to-treat . Few...
19.
Jommi C, Apolone G, Scroccaro G, Acciai V, Addis A, Ardizzoni A, et al.
Glob Reg Health Technol Assess
. 2023 Jan;
9:99-104.
PMID: 36628317
No abstract available.
20.
Di Benedetto G, Burgaletto C, Serapide M, Caltabiano R, Munafo A, Bellanca C, et al.
Int J Mol Sci
. 2022 Oct;
23(19).
PMID: 36232931
TRAIL, a member of TNF superfamily, is a potent inducer of neuronal death. Neurotoxic effects of TRAIL appear mediated by its death receptor TRAIL-R2/DR5. To assess the role of TRAIL/TRAIL-R2...